Clinical Trial

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
Protocol Amendment History 65 amendments
This ClinicalTrials.gov record has been amended 65 times since 2014-10-22; most recent amendment 2025-08-11.
Status change: Recruiting → Active, Not Recruiting 2019-10-18
Status change: Not Yet Recruiting → Recruiting 2015-02-02
Trial Details
NCT Number NCT02273375
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Intergroupe Francophone de Cancerologie Thoracique, Thoracic Oncology Group of Australasia (TOGA), National Health and Medical Research Council, Australia, National Cancer Institute, Naples, Central and Eastern European Oncology Group, Dutch Society of Physicians for Pulmonology and Tuberculosis, Korean Cancer Study Group, Fundación GECP, West Japan Oncology Group (WJOG), Chinese Thoracic Oncology Group
Conditions Non-Small Cell Lung Cancer
Enrollment 1,415 participants
Start Date 2015-02-24
Primary Completion 2025-07-23 (estimated)
Study Completion 2026-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-12